KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $686.0 million.

  • Teva Pharmaceutical Industries' Net Income towards Common Stockholders rose 34326.24% to $686.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 18796.7%. This contributed to the annual value of $1.4 billion for FY2025, which is 17112.35% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Net Income towards Common Stockholders stood at $686.0 million for Q4 2025, which was up 34326.24% from $428.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Net Income towards Common Stockholders ranged from a high of $686.0 million in Q4 2025 and a low of -$2.4 billion during Q4 2023
  • For the 5-year period, Teva Pharmaceutical Industries' Net Income towards Common Stockholders averaged around -$747.3 million, with its median value being -$744.5 million (2021).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 139420.29% in 2021, then surged by 34326.24% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Net Income towards Common Stockholders stood at -$1.1 billion in 2021, then tumbled by 90.51% to -$2.1 billion in 2022, then fell by 13.53% to -$2.4 billion in 2023, then skyrocketed by 88.33% to -$282.0 million in 2024, then soared by 343.26% to $686.0 million in 2025.
  • Its Net Income towards Common Stockholders was $686.0 million in Q4 2025, compared to $428.0 million in Q3 2025 and $274.0 million in Q2 2025.